These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 15847714)
21. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter? Michels J; Montemurro T; Murray N; Kollmannsberger C; Nguyen Chi K Cancer; 2006 Mar; 106(5):1041-6. PubMed ID: 16456811 [TBL] [Abstract][Full Text] [Related]
22. [Toxicity and efficacy of intermittent docetaxel chemotherapy for hormone refractory prostate cancer]. Olbert PJ; Weil C; Hegele A; Hofmann R; Schrader AJ Aktuelle Urol; 2009 May; 40(3):164-8. PubMed ID: 19370533 [TBL] [Abstract][Full Text] [Related]
23. [Hormonoresistant metastatic prostate cancer: analysis of two phase III clinical studies]. Ferrero JM Bull Cancer; 2005 May; 92(5):425-7. PubMed ID: 15932803 [TBL] [Abstract][Full Text] [Related]
24. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. Petrylak DP; Tangen CM; Hussain MH; Lara PN; Jones JA; Taplin ME; Burch PA; Berry D; Moinpour C; Kohli M; Benson MC; Small EJ; Raghavan D; Crawford ED N Engl J Med; 2004 Oct; 351(15):1513-20. PubMed ID: 15470214 [TBL] [Abstract][Full Text] [Related]
25. Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer? Oh WK; Tay MH; Huang J Cancer; 2007 Feb; 109(3):477-86. PubMed ID: 17186531 [TBL] [Abstract][Full Text] [Related]
26. Which drug combination for hormone-refractory prostate cancer? Doggrell SA Expert Opin Pharmacother; 2005 Apr; 6(4):667-70. PubMed ID: 15934892 [TBL] [Abstract][Full Text] [Related]
28. Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center. Zhang HL; Ye DW; Yao XD; Dai B; Zhang SL; Shen YJ; Zhu Y; Zhang W Urol Int; 2007; 79(4):307-11. PubMed ID: 18025847 [TBL] [Abstract][Full Text] [Related]
29. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Ross RW; Beer TM; Jacobus S; Bubley GJ; Taplin ME; Ryan CW; Huang J; Oh WK; Cancer; 2008 Feb; 112(3):521-6. PubMed ID: 18085595 [TBL] [Abstract][Full Text] [Related]
30. Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer. Wada Y; Kikuchi K; Takahashi W; Honda J; Nakanishi J; Matsumoto K; Kuwahara T; Kai N; Kikukawa H; Ueda S Cancer Chemother Pharmacol; 2008 Jan; 61(1):53-61. PubMed ID: 17375305 [TBL] [Abstract][Full Text] [Related]
31. Hormone refractory prostate cancer (HRPC): present and future approaches of therapy. Di Lorenzo G; De Placido S Int J Immunopathol Pharmacol; 2006; 19(1):11-34. PubMed ID: 16569343 [TBL] [Abstract][Full Text] [Related]
32. Update in the management of patients with hormone-refractory prostate cancer. Moore CN; George DJ Curr Opin Urol; 2005 May; 15(3):157-62. PubMed ID: 15815191 [TBL] [Abstract][Full Text] [Related]
33. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Rosenberg JE; Weinberg VK; Kelly WK; Michaelson D; Hussain MH; Wilding G; Gross M; Hutcheon D; Small EJ Cancer; 2007 Aug; 110(3):556-63. PubMed ID: 17577218 [TBL] [Abstract][Full Text] [Related]
34. Treatment options in hormone-refractory prostate cancer: current and future approaches. Harris KA; Reese DM Drugs; 2001; 61(15):2177-92. PubMed ID: 11772129 [TBL] [Abstract][Full Text] [Related]
37. [Chemotherapy of the hormone-refractory prostate cancer]. Heine K; Wolff JM Aktuelle Urol; 2004 Jun; 35(3):209-14. PubMed ID: 15258854 [TBL] [Abstract][Full Text] [Related]
38. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer. Nelius T; Reiher F; Lindenmeir T; Klatte T; Rau O; Burandt J; Filleur S; Allhoff EP Onkologie; 2005 Nov; 28(11):573-8. PubMed ID: 16249643 [TBL] [Abstract][Full Text] [Related]
39. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303 [TBL] [Abstract][Full Text] [Related]
40. Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer. Ferrero JM; Chamorey E; Oudard S; Dides S; Lesbats G; Cavaglione G; Nouyrigat P; Foa C; Kaphan R Cancer; 2006 Aug; 107(4):738-45. PubMed ID: 16826591 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]